News|Videos|March 6, 2025
Navigating Treatment Selection in Patients with Both ESR1 and PIK3CA Mutations and Expert Perspective for Integrating Oral SERDs into Clinical Practice
Author(s)Joyce O’Shaughnessy, MD, Alison Conlin, MD
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. O’Shaughnessy to Dr. Conlin: What is your approach to oral SERD therapy?
- For which specific patient population would you consider using single-agent elacestrant (
Bardia et al. Clin Cancer Res 2024 )? - Do you foresee elacestrant replacing fulvestrant as the endocrine therapy backbone in combination with targeted therapies?
- For which specific patient population would you consider using single-agent elacestrant (
- Dr. Conlin to Dr. O’Shaughnessy: How do you decide which mutation to target in patients who harbor both an ESR1 and PIK3CA mutation?
- Do you foresee a scientific rationale for a particular sequence/s of inhibitors of the PI3K pathway?
Advertisement
Related to this article
Tovecimig plus paclitaxel improved objective response over paclitaxel alone in previously treated advanced biliary tract cancer in COMPANION-002.
Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.
Adding durvalumab and enfortumab vedotin around cystectomy extended survival in muscle-invasive bladder cancer without cisplatin options.
Adding pembrolizumab to adjuvant radiation did not meet prespecified superiority criteria in patients with stage I/II high-intermediate–risk dMMR endometrioid endometrial cancer in the phase 3 NRG-GY020 trial.
Adding tarlatamab-dlle to durvalumab maintenance extended survival in extensive-stage small cell lung cancer in the phase 3 DeLLphi-305 trial.
Adding intismeran autogene to pembrolizumab cut the risk of recurrence and distant metastasis in resected high-risk melanoma in INTerpath-001.
Adding darolutamide to androgen deprivation and primary or salvage radiation lowered metastasis risk in very high-risk localized prostate cancer.
INCA33890 combined with standard-of-care therapy produced responses in first- and third-line metastatic microsatellite stable colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC
2
DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC
3
Adjuvant Intismeran Autogene Plus Pembrolizumab Improves RFS and DMFS in Melanoma
4
DASL-HiCaP: Darolutamide Plus ADT and Radiation Therapy Improves MFS in Very High-Risk Localized Prostate Cancer
5